See highlights from the Global Science Summit

Current Pipeline
FASTFunded
AAV-GT

UGX • GTX-102

Ultragenyx Pharmaceuticals (UGX) is exploring an investigational Antisense Oligonucleotide (ASO) approach for paternal gene activation as a potential treatment for Angelman syndrome.

Discovery & DevPre-clinicalPhase 1Phase 2Phase 3To Patients

About the Program

A therapeutic approach that uses modified RNA or DNA molecules that bind to the RNA of the UBE3A-ATS (UBE3A antisense transcript).

Investigational Drug Name
GTX-102
Company Website
Ultragenyx
Drug Name
apazunersen

Program History

In early 2012, FAST began funding Scott Dindot’s laboratory at Texas A&M University to understand the mechanism by which the UBE3A-antisense transcript (UBE3A-AS) silences the paternal UBE3A allele, why it is only silenced in neurons, and how that process may be leveraged as a potential therapy for AS. In late 2017, the Dindot laboratory identified an investigational ASO that, through preliminary studies, was shown to interfere with the imprinting mechanism of the paternal UBE3A allele in neurons, and unsilenced the gene. FAST wanted to ensure that the development of this program moved forward in the most expeditious, safe, and detailed manner possible, with the primary goal of moving into a human clinical trial if preclinical studies supported further investigation. To do this, FAST formed GeneTx Biotherapeutics LLC (GeneTx), a for-profit limited liability company, singularly focused to develop an investigational ASO for potential future use in a Phase 1/2 clinical trial for individuals living with AS.

In July 2022, GeneTX was sold to Ultragenyx Pharmaceuticals. Ultragenyx is now the sole Sponsor of the development program.

Key Researchers:

Scott DindotKey Researchers

Timeline:

  1. FAST began funding Scott Dindot’s laboratory at Texas A&M University to understand the mechanism by which the UBE3A-antisense transcript (UBE3A-AS) silences the paternal UBE3A allele, why it is only silenced in neurons, and how that process may be leveraged as a potential therapy for AS.

  2. the Dindot laboratory identified an investigational ASO that, through preliminary studies, was shown to interfere with the imprinting mechanism of the paternal UBE3A allele in neurons, and unsilenced the gene

  3. FAST created a for-profit company called GeneTx Biotherapeutics LLC specifically for one purpose: to accelerate the development of an investigational antisense oligonucleotide drug for the potential treatment of AS.

  4. the clinical trial was initiated, making this FAST-backed program the first potential disease-modifying therapy in human clinical trials for Angelman syndrome.  

  5. FAST announced that the company Ultragenyx Pharmaceuticals had exercised its option and closed on its acquisition of GeneTx Biotherapeutics LLC, a biotechnology company founded by FAST.

Questions about Clinical Trials?

Schedule a private, 1:1 appointment with Niki Armstrong, a genetic counselor who specializes in Angelman syndrome.

Meet with a Genetic Counselor

Program News

Oct 8, 2026: Ultragenyx Community Webinar

Read More

GTX-102 Phase 3 Results: What We Know, What We’re Still Learning, and Next Steps

Read More

Ultragenyx shares that GTX-102 trials will officially close on Oct 30, 2026.

Read More

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Read More

Ultragenyx launches community newsletter for Angelman syndrome.

Read More

Ultragenyx Posts a Brief Summary of the Main Results of the Phase 1/2 GTX-102 Clinical Trial.

Read More

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

Read More

Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome

Read More

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Read More

Ultragenyx Announces First Patient(s) Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

Read More

Ultragenyx Community Update October 2024

Read More

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

Read More

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Read More

Ultragenyx Pharmaceutical Ultragenyx announces completion of enrollment in Global Phase 1/2 Trial of GTX-102

Read More

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.